146 The Efficacy of Platelet-Rich Plasma (PRP) as a Supplemental Therapy for the Treatment of Erectile Dysfunction (ED): Initial Outcomes

Through past decades a variety of therapies have evolved for erectile dysfunction (ED). The effectiveness of these methods vary by individual and are often used in conjunction with each other for optimal penile rehabilitation. While the advent of platelet-rich plasma (PRP) is not new to medicine, there has been limited clinical data for its application in the field of sexual medicine, specifically in conjunction with other forms of ED therapy. Evidence suggests PRP promotes the body’s natural healing process and may help tissues in the penis better accept other therapies. This abstract provides an early review of PRP outcomes for ED. Over 12 months (8/2015 – 8/2016) patients at Midwest Urological Group were presented with the option of adding PRP to a medication and vacuum therapy regimen for the treatment of ED. Patients were excluded if they had active/metastatic cancer or any blood dyscrasias. PRP was obtained using the patients’ own plasma and each patient received only one treatment. To assess the change of erectile function, patients completed the International Index of Erectile Function (IIEF) prior to treatment and at least 4 weeks post. Patients were included in this chart review if their initial IIEF indicated moderate ED (score 10-21). Preliminary results, N = 9 patients met the criteria to be included in the present study. The mean age was 56 years (range 34-66). The average pre-PRP IIEF score was 15.6 (range 12-20). The average post- PRP IIEF was 19.9 (range 11-27). A paired samples t-test revealed no significant difference between groups, t(8) = 1.59, p= 0.157, however the effect size was large, Cohen’s d = 0.793. No adverse events were reported. 100% of patients reported no side effects. PRP may represent a safe and viable option as a supplementary therapy for penile rehabilitation. Particularly notable is the prospect of zero side effects. Further investigation is required to assess how PRP works in conjunction with specific therapies and to establish the fit within the physician’s treatment protocol. Work supported by industry: no. The presenter or any of the authors act as a consultant, employee (part time or full time) or shareholder of an industry.